AIMEDBIO

• - AimedBio has received Investigational New Drug (IND) approval from the Korean Ministry of Food and Drug Safety (MFDS) for its FGFR3-targeting ADC candidate AMB302.
  
• - The global rights to AMB302 are held by Biohaven, which initiated a Phase 1 clinical trial in the United States in March.
  
  

Link: https://m.healthcaren.com/news/news_article_yong.jsp?mn_idx=549964